Skip to main content

Diabetes

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim

    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly rolls out insulin discount program

    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     

  • Apple disrupts diabetes management with subscription service

    NEW YORK — One Drop on Tuesday announced that it has received U.S. Food and Drug Administration 510(k) clearance and Conformité Européene (CE) mark approval for One Drop | Chrome, a blood glucose monitoring system that marries modern design with advanced medical and mobile technology.

  • Genteel alternate-site lancet device gains FDA clearance

    MIDLAND, Texas — Genteel on Tuesday announced clearance by the U.S. Food & Drug Administration for its “gentle” lancing device. Genteel is the only FDA-cleared standalone lancing device that performs ample blood draw from other body sites as well as fingers.

  • How can pharmacy augment self-care trend? HRG moderator and executive panel explore value proposition

    WAUKESHA, Wis.  –  Dave Wendland, VP strategic relations and member of the owners group at Hamacher Resource Group, will moderate the Chronic Care Roundtable on Thursday, Dec. 1, at the Drug Store News Annual Industry Issues Summit. It will be Wendland’s 13th time moderating at the event, HRG stated.

  • Boehringer Ingelheim, Lilly launch campaign on Type 2 diabetes, heart disease link

    RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly & Co. have launched an educational campaign to help raise awareness of the link between heart disease and Type 2 diabetes. The “For Your SweeHeart: Where diabetes and heart disease meet” campaign launch follows a survey by the two companies that found three-in-four Americans and two-in-three people with Type 2 diabetes don’t know that heart disease is the No. 1 health-related killer of Type 2 diabetes patients. 
     

  • Sanofi’s Soliqua 100/33 for Type 2 diabetes gets FDA nod

    SILVER SPRING, Md. — The Food and Drug Administration has approved Sanofi’s Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33mcg/mL), the company announced Monday. The drug is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     

  • FDA approves Novo Nordisk’s Xultophy 100/3.6 for Type 2 diabetes

    SILVER SPRING, Md. — Novo Nordisk announced Monday that the Food and Drug Administration had approved its Xultophy 100/3.6 (insulin degludec 100 units/ML and liraglutide 3.6 mg/mL). The drug is indicated to improve glycemic control in adults with Type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily. 
     
X
This ad will auto-close in 10 seconds